Srinivas Kondapalli, MD
Ophthalmology · Pittsburgh, PANPI 1437438264
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $159,654 of the $208,233 with a category attached, or 76.7%. Regeneron Healthcare Solutions, Inc. accounts for 95.7% of it on its own, with 23 other manufacturers making up the rest. Among ophthalmology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 526 payments — averaging $395.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$199K
- Regeneron$3K
- Apellis Pharmaceuticals, Inc.$1K
- Beaver-visitec International, Inc.$1K
- Genentech USA, Inc.$783
- Dompe US, Inc.$474
- plus $2K from 18 others
Across 1 payment — averaging $7000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dompe Farmaceutici S.p.a.$7K
What the payments were for
- Consulting fees$11,3085%
- Speaking & faculty fees$159,65477%
- Travel & lodging$23,63411%
- Food & beverage$13,6187%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 396 | $199,288 |
| Regeneron | 1 | $2,825 |
| Apellis Pharmaceuticals, Inc. | 27 | $1,490 |
| Beaver-visitec International, Inc. | 1 | $1,200 |
| Genentech USA, Inc. | 21 | $783 |
| Dompe US, Inc. | 6 | $474 |
| Genentech, Inc. | 5 | $350 |
| AbbVie(2 entities) | 16 | $331 |
| Novartis | 12 | $241 |
| Sandoz | 3 | $197 |
| Astellas Pharma US Inc | 6 | $178 |
| ANI Pharmaceuticals, Inc. | 7 | $171 |
| Cardinal Health 110 LLC | 1 | $150 |
| Alimera Sciences, Inc. | 6 | $103 |
| Quidel Corporation | 2 | $95 |
| Bausch & Lomb Americas Inc. | 3 | $85 |
| Eyepoint US, Inc. | 3 | $56 |
| Coherus Oncology, Inc. | 2 | $50 |
| Aerie Pharmaceuticals, Inc. | 3 | $43 |
| Neurotech Pharmaceuticals, Inc. | 1 | $34 |
| Johnson & Johnson Vision Care, Inc. | 1 | $30 |
| Amgen | 1 | $27 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Oyster Point Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$208,233 in reported general payments places this provider in the 95th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CombiganBrimonidine Tartrate/Timolol | 25 | $6,280 |
| Prednisolone Acetate | 106 | $4,940 |
| LumiganBimatoprost | 14 | $4,540 |
| Timolol Maleate | 27 | $1,427 |
| Latanoprost | 127 | $1,254 |
| Brimonidine Tartrate | 39 | $859 |
| ValacyclovirValacyclovir Hcl | 11 | $816 |
| Ketorolac Tromethamine | 34 | $514 |
| Dorzolamide Hcl | 28 | $421 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 33 | $395 |
| ErythromycinErythromycin Base | 18 | $254 |
| Prednisone | 11 | $67 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCombigan, Lumigan | $331 | $10,82139 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 920 ophthalmology providers in Pennsylvania.
Other ophthalmology in Pittsburgh
- Francis MahPittsburgh$1.1M
- Robert NoeckerPittsburgh$632K
- Deval ParanjpePittsburgh$121K
- Ian ConnerPittsburgh$82K
- Deepinder DhaliwalPittsburgh$65K
- Thomas FribergPittsburgh$55K
- Jenny YuPittsburgh$47K
- Vishal JhanjiPittsburgh$38K
- Omar AbbasiPittsburgh$36K
- Julia HallerPhiladelphia$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.